Pacira BioSciences (NASDAQ:PCRX) is a biopharmaceutical company specializing in non-opioid pain management and regenerative health solutions. Founded in 2006 and headquartered in Parsippany, New Jersey, the company is dedicated to developing innovative therapies that address acute and chronic pain while reducing reliance on opioid medications. Pacira’s research and development efforts focus on advanced drug delivery technologies designed to improve patient outcomes in surgical and postoperative settings.
The company’s flagship product, EXPAREL, is a liposomal bupivacaine injection that provides sustained postoperative analgesia for up to 72 hours, helping to reduce opioid consumption and enhance recovery protocols. Pacira also offers the iovera® cryoanalgesia system, which uses targeted cryotherapy to temporarily block nerve conduction and provide localized pain relief for orthopedic and surgical applications. In addition to commercial offerings, the company maintains a robust pipeline of investigational therapies aimed at expanding its portfolio of non-opioid analgesics and regenerative health products.
Pacira operates globally, with a commercial presence in North America, Europe, Latin America and the Asia Pacific region. The company works closely with hospitals, ambulatory surgery centers and specialty clinics to integrate its products into multimodal pain management pathways, offering training and education programs for anesthesiologists, surgeons and nursing professionals. Strategic partnerships and distribution agreements further support Pacira’s efforts to broaden access to its proprietary drug delivery platforms.
Under the leadership of President and Chief Executive Officer Jeremy A. Jacobs, Pacira has strengthened its operational capabilities and expanded its international reach. Supported by a seasoned executive team with expertise in pharmaceutical development, regulatory affairs and commercial strategy, the company continues to advance its mission of delivering safer, more effective pain management solutions and regenerative health innovations.
